TRIKAFTA may give patients with cystic fibrosis hope for healthy pregnancies. Learn about the landmark clinical trial to analyze its safety from pregnancy through two years after delivery.
A new 3-drug combo drug for cystic fibrosis has been approved by the FDA. TRIKAFTA offers life-changing treatment potential for approximately 90% of patients with the disease. In this MedBlog, discover who is eligible and how the drug works. Learn more.
Babies and children who don't get proper nutrition can develop failure to thrive, a condition that causes delayed growth and poor brain development. In this MedBlog, find three common causes and strategies families can use to improve their child's health. Learn more.
Traditionally, patients with cystic fibrosis have been treated with inhaled medications that could affect the lungs with limited systemic effects. However, a relatively new set of drugs, CFTR modulators, offer an oral alternative with the potential to slow the progression of the disease for up to 90 percent of patients.
